Related Image:
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq: APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant. Venaxis has ...
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... Calif. , May 23, 2013 Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics ... company developing DCVax ® personalized immune therapies for ... its exhibit at this year,s American Society Of Clinical ... to highlight its leadership role in immune therapy. ... ASCO annual meeting is the pre-eminent conference focused on ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA ),a ... it,begins the production of a vaccine against influenza A (H1N1) virus. ... the company on June 8, 2009. , ... midst of a global outbreak and transmission of H1N1, our mission ...
... Device to Membership , , , COLD SPRING ... three year agreement with Amerinet Inc. to offer the AccuVein ... its members. The AccuVein AV300 projects a pattern of ... the healthcare professional locate veins for blood draw (venipuncture), IV ...
... -- Pasteuria Bioscience announced that it has received ... Pasteuria usgae . This is a critical step ... natural bacteria prevalent in soil that have long been recognized ... , , "We,re very pleased to receive this EPA ...
Cached Biology Technology:Sinovac Begins the Production of Influenza A (H1N1) Vaccine 2Sinovac Begins the Production of Influenza A (H1N1) Vaccine 3AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet 2Pasteuria Bioscience Receives EPA Registration for Nematode Control 2...
... contains the basic components required for the ... and recombinant canine Monocyte Chemotactic Protein 1 ... Each kit contains sufficient materials to run ... that the following conditions are met:2 ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu Insertion Kit...
Biology Products:Biology NavigationMedical Navigation